Literature DB >> 26482334

Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.

Shunsuke Yamada1,2, Kenji Ueki1, Masanori Tokumoto2, Takaichi Suehiro1, Hiroshi Kimura1,3, Masatomo Taniguchi1, Satoru Fujimi3, Takanari Kitazono1, Kazuhiko Tsuruya1,4.   

Abstract

Selection of a lower dialysate calcium concentration (DCa) can reduce calcium burden and prevent vascular calcification in hemodialysis patients. However, decreased DCa can worsen mineral and bone disorders. This 1-year retrospective observational study evaluated 121 hemodialysis patients at Fukuoka Renal Clinic who underwent conversion of DCa from 3.0 mEq/L to 2.75 mEq/L. The primary outcomes were changes in serum levels of calcium, phosphate, and parathyroid hormone (PTH). The effects of baseline serum calcium and PTH levels on changes in biochemical parameters were also determined. One year after DCa conversion, mean serum calcium level decreased, while serum phosphate, alkaline phosphatase, and PTH concentrations increased. The rate of achievement of target PTH was higher in patients with lower serum PTH level at baseline, while patients with higher baseline serum PTH level tended to exceed the upper limit of the PTH target range. Patients with higher baseline serum calcium concentration showed a greater decrease in serum calcium level and a greater increase in serum PTH level at 1 year. Patients with a lower baseline serum PTH level can benefit from optimal PTH control following conversion of DCa from 3.0 mEq/L to 2.75 mEq/L. However, secondary hyperparathyroidism may be exacerbated in some patients with higher baseline serum calcium (Ca) and PTH levels. These results indicate that an individualized approach can maximize the benefits of Ca unloading after conversion to lower DCa.
© 2015 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  Chronic kidney disease-mineral and bone disorder; Dialysate calcium concentration; Hemodialysis; Parathyroid hormone; Secondary hyperparathyroidism

Mesh:

Substances:

Year:  2015        PMID: 26482334     DOI: 10.1111/1744-9987.12329

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  3 in total

1.  Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.

Authors:  Kunitoshi Iseki; Daijiro Kabata; Tetsuo Shoji; Masaaki Inaba; Masanori Emoto; Katsuhito Mori; Tomoaki Morioka; Shinya Nakatani; Ayumi Shintani
Journal:  PLoS One       Date:  2022-09-07       Impact factor: 3.752

2.  Short- and Long-term Effects of Dialysate Calcium Concentrations on Mineral and Bone Metabolism in Hemodialysis Patients: The K4 Study.

Authors:  Teppei Sakoh; Masatomo Taniguchi; Shunsuke Yamada; Shotaro Ohnaka; Hokuto Arase; Masanori Tokumoto; Taihei Yanagida; Koji Mitsuiki; Hideki Hirakata; Toshiaki Nakano; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Kidney Med       Date:  2019-09-11

3.  Higher dialysate calcium concentration is associated with incident myocardial infarction among diabetic patients with low bone turnover: a longitudinal study.

Authors:  Miho Tagawa; Takayuki Hamano; Shinichi Sueta; Satoshi Ogata; Yoshihiko Saito
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.